Prevalence of rs2108622 (CYP4F2*3) Single Nucleotide Polymorphism – A Review
Cardiovascular diseases are known to be treated with anticoagulants lifelong. Warfarin is one of the most commonly used medications for anticoagulation despite causing serious side effects in some patients. Different single nucleotide polymorphisms (SNPs) that have a role in the cytochrome P450 system can also affect the metabolism, as well as dosing, of warfarin. The purpose of this review is to look into the prevalence of this SNP in the past research and screen for possible correlations with age, place of origin, family history of cardiovascular and cerebrovascular diseases, or other medical conditions possibly present in various populations. In total, 20 scientific articles falling under the inclusion criteria were reviewed and found usable, and the rest of the cases will be highly beneficial in the upcoming years to determine the role of the recently discovered CYP4F2 rs2108622 variant, as well as the previously known CYP2C9 and VKORC1 SNPs, in the variance of warfarin dose requirement. These findings may also point researchers in the right direction for qualifying and validating these genetic variants for use as GBs (genomic biomarkers) in the clinical and medical practice of treatment with warfarin.